Evaluating the efficacy and safety of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-positive metastatic gastro-esophageal junction and gastric cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-003554-83

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To compare overall survival (OS) in patients treated with pertuzumab in addition to Herceptin® (trastuzumab) plus fluoropyrimidine plus cisplatin (TFP) versus patients treated with placebo in addition to TFP


Critère d'inclusion

  • HER2-positive advanced gastroesophageal junction/gastric cancer